The Efficacy and Safety of First-Line Metastatic Melanoma Treatment with Ipilimumab + Nivolumab Versus Nivolumab in a Real-World Setting

Investigators compared the efficacy and safety of nivolumab to ipilimumab + nivolumab as first-line treatment for metastatic melanoma. A total of 406 patients were treated with nivolumab, and 416 with ipilimumab + nivolumab.